ifosfamide has been researched along with Benign Cranial Nerve Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mappa, S | 1 |
| Marturano, E | 1 |
| Licata, G | 1 |
| Frezzato, M | 1 |
| Frungillo, N | 1 |
| Ilariucci, F | 1 |
| Stelitano, C | 1 |
| Ferrari, A | 1 |
| Sorarù, M | 1 |
| Vianello, F | 1 |
| Baldini, L | 1 |
| Proserpio, I | 1 |
| Foppoli, M | 1 |
| Assanelli, A | 1 |
| Reni, M | 1 |
| Caligaris-Cappio, F | 1 |
| Ferreri, AJ | 1 |
| Kirch, C | 1 |
| Gachot, B | 1 |
| Germann, N | 1 |
| Blot, F | 1 |
| Nitenberg, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for ifosfamide and Benign Cranial Nerve Neoplasms
| Article | Year |
|---|---|
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Centra | 2013 |
Recurrent ifosfamide-induced hyponatraemia.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Cranial Nerve Neoplasms; Female; Humans; Hyponatremia | 1997 |